Premium
Olanzapine in Cocaine Dependence: A Double‐Blind, Placebo‐Controlled Trial
Author(s) -
Hamilton Joseph D.,
Nguyen Quang X.,
Gerber Robert M.,
Rubio Nancy B.
Publication year - 2009
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1080/10550490802544318
Subject(s) - olanzapine , placebo , cocaine dependence , extrapyramidal symptoms , psychology , dopamine antagonist , craving , psychiatry , medicine , addiction , anesthesia , schizophrenia (object oriented programming) , antipsychotic , haloperidol , dopamine , alternative medicine , pathology
Preclinical and uncontrolled human studies have suggested the possible efficacy of second‐generation antipsychotics, particularly olanzapine, in treating cocaine dependence. We conducted a randomized, double‐blind, placebo‐controlled trial in which 48 cocaine‐dependent subjects received olanzapine or identical‐appearing placebo for 16 weeks. The primary outcome measure was the proportion of cocaine‐negative weekly urine screens during treatment. Secondary measures included scores on a Craving Questionnaire, Addiction Severity Index subscales, and extrapyramidal symptom scales. Olanzapine and placebo did not differ on any outcome measure. Both olanzapine and placebo subjects frequently reported side effects, but no unexpected ones. We conclude that olanzapine appears ineffective for cocaine dependence.